JHS Svendgaard Laboratories
- Market cap
- ₹ 74 Cr.
- P/E
- 28.3x
- P/B
- 0.44x
- 52-week range
- 6.26 – 13.69
- ROE
- −1%
- ROCE
- −1%
- Dividend yield
- 0%
- Debt / equity
- 0.09
- Sector
- Personal Products
- Industry
- Personal Care
- Listed on
- NSE, BSE
About
JHS Svendgaard Laboratories Limited is an India-based private label manufacturer of oral care products. The Company is engaged in manufacturing a range of oral and dental products for national and international brands. The Company is involved in the manufacturing and exporting of oral care and hygiene products, including toothbrushes, toothpastes, mouthwash, sanitizers and job work of detergent powder. Its domestic market products include toothbrushes, toothpaste, mouthwash, laundry sanitizer, and room fresheners. Its international market products include toothbrush, toothpaste and denture tablet. The Company’s subsidiary is JHS Svendgaard Mechanical and Warehouse Private Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Personal Care: 22 companies →JHS Svendgaard Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)28.3 against a typical 33.9: cheaper than most peers (1st = cheapest).8th of 22
- Sales growth+29.6% against a typical +14.9% from a year earlier.3rd of 15
- Profit growth+2.8% against a typical +8.9% from a year earlier.9th of 13
- Share price, 3 months+41% against a typical −7.5%.2nd of 19
- Size₹ 74.1 Cr. market value against a typical ₹ 188.1 Cr. (1st = largest).14th of 19
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 2 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 11 Aug 2026 | Financial Results | To consider and approve the Un-Audited financial results (Standalone and Consolidated) for the period ended Jun 30, 2026 |
| 26 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 10 Feb 2026 | Financial Results | To consider and approve the un-audited financial results for the period ended December 31, 2025 |
| 14 Nov 2025 | Financial Results | The Company has informed the Exchange that a Board meeting to be held on November 13, 2025 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on November 14, 2025, To consider and approve the financial results for the period ended September 30, 2025 |
| 13 Nov 2025 | Financial Results | To consider and approve the un-audited financial results for the quarter and half year ended September 30, 2025 |
| 21 Aug 2025 | Other business matters | To consider and approve the JHS Svendgaard Laboratories Employee Stock Option Scheme 2025 ( Scheme ). |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19 | 14 | 22 | 24 | 20 | 23 | 25 | 23 | 22 | 23 | 33 | 30 |
| Expenses | 19 | 14 | 21 | 23 | 21 | 22 | 31 | 22 | 21 | 22 | 34 | 28 |
| Operating Profit | 0 | −0 | 1 | 2 | −1 | 0 | −5 | 2 | 1 | 2 | −2 | 2 |
| OPM % | 2.2% | −0.4% | 3.9% | 8.1% | −4.3% | 1.1% | −21.4% | 7.1% | 4.1% | 7.2% | −5% | 6.8% |
| Other Income | 0 | 2 | 1 | 0 | 1 | 0 | −1 | 1 | 1 | 1 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | −1 | 1 | 0 | 0 | −2 | −2 | −9 | 1 | −0 | 0 | −3 | 0 |
| Tax % | −26.3% | 100% | 516.7% | 415% | 398.1% | 15.8% | −23.1% | −69.4% | 1,800% | −887.5% | 19.7% | −1,716.7% |
| Net Profit | −1 | 0 | −1 | −1 | −10 | −2 | −7 | 1 | −0 | 1 | −4 | 1 |
| EPS in Rs | −0.09 | 0 | −0.1 | −0.08 | −1.21 | −0.21 | −0.81 | 0.12 | −0.02 | 0.09 | −0.41 | 0.12 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 0%
- 5 Years
- 0%
- 3 Years
- 6%
- TTM
- 19%
- 10 Years
- 4%
- 5 Years
- —
- 3 Years
- —
- TTM
- 88%
- 10 Years
- −13%
- 5 Years
- −19%
- 3 Years
- −33%
- TTM
- —
- 10 Years
- 2%
- 5 Years
- −1%
- 3 Years
- −5%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| JHS Svendgaard Laboratories | ₹ 10.53 | ₹ 74 Cr. | 28.3x | 0.4x | −1% | — |
| Hindustan Unilever | ₹ 1,820.00 | ₹ 4,27,626 Cr. | 48.3x | 10.3x | 21.5% | 16.1% |
| Godrej Consumer Products | ₹ 851.50 | ₹ 87,134 Cr. | 54.2x | 8.7x | 15.1% | 12.3% |
| Marico | ₹ 764.10 | ₹ 99,347 Cr. | 62.2x | 26x | 43.1% | 13.3% |
| Dabur India | ₹ 366.00 | ₹ 64,927 Cr. | 40x | 6.6x | 17.1% | 14.2% |
| Cupid | ₹ 306.50 | ₹ 41,214 Cr. | 271.9x | 64.1x | 27.3% | 30.3% |
Management
- Paramvir Singh Pabla
- Chief Executive Officer, Executive Director
- Ashish Goel
- Chief Financial Officer
- Komal Jha
- Compliance Officer, Company Secretary
- Nikhil Nanda
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.